# Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

> **NCT03171064** · PHASE2 · COMPLETED · sponsor: **University Hospital Heidelberg** · enrollment: 39 (actual)

## Conditions studied

- PD-1 Antibodies
- Exercise
- Melanoma

## Interventions

- **BEHAVIORAL:** Resistance and Endurance Exercise

## Key facts

- **NCT ID:** NCT03171064
- **Lead sponsor:** University Hospital Heidelberg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-12-01
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03171064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03171064, "Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03171064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*